Aventis and Graffinity Sign Drug Development Deal | GenomeWeb

NEW YORK, May 31 - Aventis Pharma and chemical microarray developer Graffinity Pharmaceutical Design have signed a collaboration to identify leads for Aventis' drug targets, the two companies said Thursday. 

Financial details were not disclosed.

Graffinity, based in Heidelberg, Germany, has developed small-molecule microarrays that identify which compounds bind favorably with a protein drug target. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.